


## BAY-298

Cat. No.:	HY-130249		
CAS No.:	2471978-97-7		
Molecular Formula:	C <sub>27</sub> H <sub>21</sub> ClFN <sub>3</sub> O <sub>2</sub>		
Molecular Weight:	473.93		
Target:	GnRH Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (211.00 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.1100 mL	10.5501 mL	21.1002 mL
		5 mM		0.4220 mL	2.1100 mL	4.2200 mL
10 mM			0.2110 mL	1.0550 mL	2.1100 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.28 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	BAY-298 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC <sub>50</sub> s of 96 nM, 23 nM and 78 nM for hLH (human LH) and rLH (rat LH) and cLH (cynomolgus monkey LH), respectively. BAY-298 can reduce sex hormone levels <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 185 nM (hLH), 46nM (rLH) and 78 nM (cLH) <sup>[1]</sup>
In Vivo	<p>BAY-298 (oral; 4.5-72 mg/kg/day; for 8 days) dosedependently lowers serum estradiol levels in proestrus<sup>[1]</sup>.</p> <p>BAY-298 (iv of 0.5 mg/kg or po of 2 mg/kg) has t<sub>1/2</sub>s of 31 hours and 33 hours for iv and po. And the C<sub>max</sub>s are 0.28 kg/L and 0.066 kg/L for iv and po<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

Animal Model:	Intact female rats <sup>[1]</sup>
Dosage:	4.5, 9, 18, 36, 72 mg/kg
Administration:	Oral; for 8 days
Result:	Dosedependently lowered serum estradiol levels in proestrus.
Animal Model:	Female and male Wistar rats <sup>[1]</sup>
Dosage:	0.5 mg/kg of iv or 2 mg/kg of po
Administration:	Iv or po
Result:	Has $t_{1/2}$ s of 31 hours and 33 hours for iv and po. And the $C_{max}$ s are 0.28 kg/L and 0.066 kg/L for iv and po.

## REFERENCES

[1]. Wortmann L, et al. Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels In Vivo. J Med Chem. 2019 Oct 31.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA